Fulgent Genetics EBITDA Margin 2015-2023 | FLGT
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Fulgent Genetics (FLGT) over the last 10 years. The current EBITDA margin for Fulgent Genetics as of December 31, 2023 is .
| Fulgent Genetics EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2023-12-31 | $0.29B | $-0.05B | -18.28% |
| 2023-09-30 | $0.29B | $-0.05B | -18.47% |
| 2023-06-30 | $0.31B | $-0.05B | -15.26% |
| 2023-03-31 | $0.37B | $-0.01B | -3.01% |
| 2022-12-31 | $0.62B | $0.22B | 34.89% |
| 2022-09-30 | $0.80B | $0.40B | 49.56% |
| 2022-06-30 | $0.93B | $0.55B | 59.68% |
| 2022-03-31 | $0.95B | $0.63B | 66.35% |
| 2021-12-31 | $0.99B | $0.69B | 69.89% |
| 2021-09-30 | $1.04B | $0.77B | 73.94% |
| 2021-06-30 | $0.91B | $0.67B | 73.08% |
| 2021-03-31 | $0.77B | $0.57B | 73.09% |
| 2020-12-31 | $0.42B | $0.29B | 69.67% |
| 2020-09-30 | $0.14B | $0.07B | 48.89% |
| 2020-06-30 | $0.04B | $0.00B | 9.30% |
| 2020-03-31 | $0.03B | $0.00B | 5.88% |
| 2019-12-31 | $0.03B | $0.00B | 6.45% |
| 2019-09-30 | $0.03B | $0.00B | 6.90% |
| 2019-06-30 | $0.03B | 0 | 0.00% |
| 2019-03-31 | $0.02B | $-0.00B | -4.55% |
| 2018-12-31 | $0.02B | $-0.00B | -9.09% |
| 2018-09-30 | $0.02B | $-0.00B | -20.00% |
| 2018-06-30 | $0.02B | $-0.01B | -26.32% |
| 2018-03-31 | $0.02B | $-0.01B | -26.32% |
| 2017-12-31 | $0.02B | $-0.00B | -10.53% |
| 2017-09-30 | $0.02B | $0.00B | 9.52% |
| 2017-06-30 | $0.02B | $0.00B | 14.29% |
| 2017-03-31 | $0.02B | $0.00B | 20.00% |
| 2016-12-31 | $0.02B | $0.00B | 16.67% |
| 2016-06-30 | $0.01B | $0.00B | 20.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.601B | $0.289B |
| Fulgent Genetics, Inc. provides genetic testing services to physicians with clinically actionable diagnostic information. The company's technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics is headquartered in Temple City, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GE HealthCare Technologies (GEHC) | United States | $39.354B | 21.89 |
| Inspire Medical Systems (INSP) | United States | $7.194B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $3.483B | 0.00 |
| Axonics (AXNX) | United States | $3.401B | 0.00 |
| 10x Genomics (TXG) | United States | $3.288B | 0.00 |
| Enovis (ENOV) | United States | $3.030B | 23.02 |
| Azenta (AZTA) | United States | $2.910B | 237.18 |
| Olink Holding AB (publ) (OLK) | Sweden | $2.840B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $2.678B | 0.00 |
| Privia Health (PRVA) | United States | $2.167B | 96.11 |
| Schrodinger (SDGR) | United States | $1.733B | 0.00 |
| Omnicell (OMCL) | United States | $1.279B | 31.30 |
| Phreesia (PHR) | United States | $1.162B | 0.00 |
| Definitive Healthcare (DH) | United States | $0.823B | 0.00 |
| Standard BioTools (LAB) | United States | $0.708B | 0.00 |
| Talkspace (TALK) | United States | $0.527B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.353B | 0.00 |
| Clover Health Investments (CLOV) | United States | $0.337B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.328B | 0.00 |
| Pulmonx (LUNG) | United States | $0.281B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.162B | 0.00 |
| American Well (AMWL) | United States | $0.153B | 0.00 |
| MSP Recovery (LIFW) | United States | $0.141B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.141B | 0.00 |
| Augmedix (AUGX) | United States | $0.139B | 0.00 |
| Outset Medical (OM) | United States | $0.124B | 0.00 |
| TruBridge (TBRG) | United States | $0.118B | 5.03 |
| 111 (YI) | China | $0.086B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.082B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.073B | 0.00 |
| HeartBeam (BEAT) | United States | $0.053B | 0.00 |
| Zepp Health (ZEPP) | China | $0.052B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.048B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.035B | 0.00 |
| Movano (MOVE) | United States | $0.026B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.023B | 0.00 |
| Cue Health (HLTH) | United States | $0.022B | 0.00 |
| Akili (AKLI) | United States | $0.019B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.019B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.018B | 0.00 |
| CareCloud (CCLD) | United States | $0.017B | 0.00 |
| ETAO (ETAO) | United States | $0.015B | 0.00 |
| Biotricity (BTCY) | United States | $0.012B | 0.00 |
| Transgenomic (PRPO) | United States | $0.009B | 0.00 |
| HeartSciences (HSCS) | United States | $0.006B | 0.00 |
| Syra Health (SYRA) | United States | $0.006B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.006B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.006B | 0.00 |
| Zhongchao (ZCMD) | China | $0.003B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Centogene (CNTG) | Germany | $0.000B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.000B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.000B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.000B | 0.00 |